CAM
EW icon

Chesapeake Asset Management’s Edwards Lifesciences EW Stock Holding History

Chesapeake Asset Management’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-10
Closed -$724 – 394
2025
Q1 		$724 Buy
10
+5
+100% +$358 ﹤0.01% 399
2024
Q4 		$370 Hold
5
– – ﹤0.01% 432
2024
Q3 		$329 Buy
+5
New +$363 ﹤0.01% 429
2023
Q2 		– Sell
-1,461
Closed -$121K – 459
2023
Q1 		$121K Buy
+1,461
New +$115K 0.11% 107

Other funds holding EW

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
DZ Bank
DZ Bank Frankfurt Am Main, Germany $130B AUM 46.38% 1-Year Est. Return

Chesapeake Asset Management's EW Position: Q2 2025 in Review

Chesapeake Asset Management sold out of Edwards Lifesciences (EW) in Q2 2025, closing a stake of 10 shares — an estimated $724 sold.

Chesapeake Asset Management first reported a position in EW in Q1 2023 and held it in 4 quarters. The position peaked at $121K in Q1 2023. 1,261 funds tracked by Wall St. Rank hold EW as of Q2 2025.

  • Chesapeake Asset Management reported no remaining Edwards Lifesciences position as of Q2 2025 after selling out during the quarter.
  • Chesapeake Asset Management sold 10 Edwards Lifesciences shares in Q2 2025, an estimated $724.
  • Chesapeake Asset Management first reported a position in Edwards Lifesciences in Q1 2023 and held it in 4 quarters.
  • Chesapeake Asset Management's Edwards Lifesciences position peaked at $121K in Q1 2023.
  • 1,261 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2025.

Based on Chesapeake Asset Management's 13F filing for Q2 2025, filed 15 Oct 2025.